TRESK2

1

Veale EL et al. Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels.
Br. J. Pharmacol., 2016 May , 173 (1639-52).

2

Hwang HY et al. TWIK-Related Spinal Cord K⁺ Channel Expression Is Increased in the Spinal Dorsal Horn after Spinal Nerve Ligation.
Yonsei Med. J., 2015 Sep , 56 (1307-15).

3

Enyedi P et al. Properties, regulation, pharmacology, and functions of the K₂p channel, TRESK.
Pflugers Arch., 2015 May , 467 (945-58).

4

Mathie A et al. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.
Pflugers Arch., 2015 May , 467 (931-43).

5

Tsantoulas C Emerging potassium channel targets for the treatment of pain.
Curr Opin Support Palliat Care, 2015 Jun , 9 (147-54).

6

Green EW et al. Drosophila circadian rhythms in seminatural environments: Summer afternoon component is not an artifact and requires TrpA1 channels.
Proc. Natl. Acad. Sci. U.S.A., 2015 Jul 14 , 112 (8702-7).

7

Kubota K et al. Hydroxy-α sanshool induces colonic motor activity in rat proximal colon: a possible involvement of KCNK9.
Am. J. Physiol. Gastrointest. Liver Physiol., 2015 Apr 1 , 308 (G579-90).

8

Braun G et al. Differential sensitivity of TREK-1, TREK-2 and TRAAK background potassium channels to the polycationic dye ruthenium red.
Br. J. Pharmacol., 2015 Apr , 172 (1728-38).

9

Czirják G et al. The LQLP calcineurin docking site is a major determinant of the calcium-dependent activation of human TRESK background K+ channel.
J. Biol. Chem., 2014 Oct 24 , 289 (29506-18).

10

Rainero I et al. KCNK18 (TRESK) genetic variants in Italian patients with migraine.
Headache, 2014 Oct , 54 (1515-22).

11

Guo Z et al. Non-migraine associated TRESK K+ channel variant C110R does not increase the excitability of trigeminal ganglion neurons.
J. Neurophysiol., 2014 May 7 , ().

12

Rahm AK et al. Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2014 Mar , 387 (291-300).

13

Bruner JK et al. Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel.
Eur. J. Pharmacol., 2014 Jun 24 , ().

14

Gohlke BO et al. SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res., 2014 Jan 1 , 42 (D1107-12).

15

Guo Z et al. Over-expression of TRESK K(+) channels reduces the excitability of trigeminal ganglion nociceptors.
PLoS ONE, 2014 , 9 (e87029).

16

Enyedi P et al. Tubulin binds to the cytoplasmic loop of TRESK background K⁺ channel in vitro.
PLoS ONE, 2014 , 9 (e97854).

17

Sehgal SA et al. Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18.
Drug Des Devel Ther, 2014 , 8 (571-81).

18

Wright PD et al. Cloxyquin (5-Chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK.
Biochem. Biophys. Res. Commun., 2013 Oct 25 , ().

19

Maher BH et al. Analysis of 3 common polymorphisms in the KCNK18 gene in an Australian Migraine case-control cohort.
Gene, 2013 Oct 10 , 528 (343-6).

20

Wright PD et al. Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK.
Biochem. Biophys. Res. Commun., 2013 Nov 15 , 441 (463-8).

21

Pollema-Mays SL et al. Expression of background potassium channels in rat DRG is cell-specific and down-regulated in a neuropathic pain model.
Mol. Cell. Neurosci., 2013 Nov , 57 (1-9).

22

Callejo G et al. Modulation of TRESK background K+ channel by membrane stretch.
PLoS ONE, 2013 , 8 (e64471).